KOLINPHARMA
I prodotti Kolinpharma
News
From Kolinpharma world
16/04/2020
KOLINPHARMA®:first patent for XINEPA® in Israel and fifth outside Italy

Xinepa® is a nutraceutical product already in possession of a double patent in Italy, of technology and formula, which has been recognized for the innovation and uniqueness of the composition intended for the treatment of neuropathies and neuropathic pain by one of the most advanced countries in the world in the #nutraceutical market.

 

It is the result of research carried out by Kolinpharma which has demonstrated its mechanism of action and validity through in vitro and clinical studies, the results of which have been published in International Technical-Scientific Journals.

Rita Paola Petrelli, President of Kolinpharma®, comments: "Our strategy of competitive positioning in key countries outside of Italy continues, through the certification of the most innovative products in our portfolio.

Israel is a pioneering country, with high levels of control and restrictions also due to Kosher regulations, the new patent represents for us a source of pride and a confirmation of the quality of our R&D activity with increasingly innovative and effective products. "

 

 


< Back
Ultime news
KOLINPHARMA<sup>®</sup> “Growth Leader 2022” for the fourth consecutive year
19/11/2021
KOLINPHARMA® “Growth Leader 2022” for the fourth consecutive year
Kolinpharma<sup>®</sup> at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
05/08/2021
Kolinpharma® at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
Metatag
Respect the environment, Certified products, Corporate compliance, Nutraceuticals , Profile and organization, Research and development, Consumer Protection, Xinepa Easy and tablets
“Science accuracy and listen to people”
“Science accuracy and listen to people”